Exeter Financial LLC purchased a new stake in Bristol-Myers Squibb Co (NYSE:BMY) during the 1st quarter, HoldingsChannel reports. The institutional investor purchased 5,193 shares of the biopharmaceutical company’s stock, valued at approximately $248,000.

Several other institutional investors have also made changes to their positions in the company. Martingale Asset Management L P increased its holdings in Bristol-Myers Squibb by 12.7% during the 3rd quarter. Martingale Asset Management L P now owns 556,353 shares of the biopharmaceutical company’s stock worth $34,540,000 after purchasing an additional 62,836 shares during the period. Standard Life Aberdeen plc increased its holdings in Bristol-Myers Squibb by 9.9% during the 3rd quarter. Standard Life Aberdeen plc now owns 533,866 shares of the biopharmaceutical company’s stock worth $33,143,000 after purchasing an additional 48,146 shares during the period. Dodge & Cox increased its holdings in Bristol-Myers Squibb by 0.8% during the 3rd quarter. Dodge & Cox now owns 32,969,186 shares of the biopharmaceutical company’s stock worth $2,046,727,000 after purchasing an additional 264,100 shares during the period. Thrivent Financial for Lutherans increased its holdings in Bristol-Myers Squibb by 1.7% during the 3rd quarter. Thrivent Financial for Lutherans now owns 81,120 shares of the biopharmaceutical company’s stock worth $5,036,000 after purchasing an additional 1,358 shares during the period. Finally, Mackenzie Financial Corp increased its holdings in Bristol-Myers Squibb by 23.7% during the 3rd quarter. Mackenzie Financial Corp now owns 122,869 shares of the biopharmaceutical company’s stock worth $7,628,000 after purchasing an additional 23,543 shares during the period. 74.28% of the stock is currently owned by institutional investors and hedge funds.

Several brokerages have weighed in on BMY. BMO Capital Markets upped their price target on Bristol-Myers Squibb from $62.00 to $63.00 and gave the stock an “outperform” rating in a report on Wednesday, April 17th. Zacks Investment Research upgraded Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a report on Monday, April 8th. ValuEngine downgraded Bristol-Myers Squibb from a “sell” rating to a “strong sell” rating in a report on Thursday, April 4th. Bank of America cut their price target on Bristol-Myers Squibb from $53.00 to $51.00 and set a “neutral” rating on the stock in a report on Tuesday, February 19th. Finally, Credit Suisse Group restated a “hold” rating and set a $59.00 price target on shares of Bristol-Myers Squibb in a report on Friday, February 15th. One analyst has rated the stock with a sell rating, eleven have given a hold rating and six have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $59.14.

BMY opened at $45.24 on Tuesday. Bristol-Myers Squibb Co has a one year low of $44.30 and a one year high of $63.69. The stock has a market capitalization of $74.38 billion, a PE ratio of 11.37, a price-to-earnings-growth ratio of 2.34 and a beta of 0.79. The company has a current ratio of 1.61, a quick ratio of 1.50 and a debt-to-equity ratio of 0.40.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, January 24th. The biopharmaceutical company reported $0.94 EPS for the quarter, beating analysts’ consensus estimates of $0.85 by $0.09. Bristol-Myers Squibb had a return on equity of 48.99% and a net margin of 21.95%. The business had revenue of $5.97 billion for the quarter, compared to the consensus estimate of $5.95 billion. During the same quarter in the prior year, the business posted $0.68 EPS. The business’s revenue for the quarter was up 9.6% on a year-over-year basis. On average, research analysts expect that Bristol-Myers Squibb Co will post 4.16 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th will be issued a $0.41 dividend. The ex-dividend date is Thursday, April 4th. This represents a $1.64 dividend on an annualized basis and a dividend yield of 3.63%. Bristol-Myers Squibb’s payout ratio is currently 41.21%.

WARNING: “Exeter Financial LLC Purchases Shares of 5,193 Bristol-Myers Squibb Co (BMY)” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this news story on another website, it was stolen and republished in violation of US & international copyright & trademark laws. The correct version of this news story can be accessed at https://www.watchlistnews.com/exeter-financial-llc-purchases-shares-of-5193-bristol-myers-squibb-co-bmy/2982018.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Featured Article: Market Capitalization – What it Means for Investors

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.